The nuclear factor-κB pathway regulates cytochrome P450 3A4 protein stability

Molecular Pharmacology

Volumn 73, Issue 6, 2008, Pages 1652-1658

  Zangar, Richard C ^a,c   Bollinger, N ^a   Verma, S ^a   Karin, N J ^a   Lu, Y ^b  

^a PACIFIC NORTHWEST NATIONAL LABORATORY   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CYCLOHEXIMIDE; CYTOCHROME P450 3A4; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEASOME;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CANCER CELL; DNA BINDING; DRUG ACTIVITY; DRUG INHIBITION; HUMAN; HUMAN CELL; LIVER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY; PROTEIN SYNTHESIS;

CELL LINE; CELL LINE, TUMOR; CYTOCHROME P-450 CYP3A; ENZYME STABILITY; HEPATOCYTES; HUMANS; NF-KAPPA B; PROTEASOME ENDOPEPTIDASE COMPLEX; SIGNAL TRANSDUCTION;

EID: 44249092995     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.107.043976     Document Type: Article

References (36)

1. Akiyama TE and Gonzalez FJ (2003) Regulation of P450 genes by liver-enriched transcription factors and nuclear receptors. Biochim Biophys Acta 1619:223-234.
2. Brimer C, Dalton JT, Zhu Z, Schuetz J, Yasuda K, Vanin E, Relling MV, Lu Y, and Schuetz EG (2000) Creation of polarized cells coexpressing CYP3A4, NADPH cytochrome P450 reductase and MDR1/P-glycoprotein. Pharm Res 17:803-810.
3. Correia MA, Yao K, Wrighton SA, Waxman DJ, and Rettie AE (1992) Differential apoprotein loss of rat liver cytochromes P450 after their inactivation by 3,5-dicarbethoxy-2,6-dimethyl-4-ethyl-1,4-dihydropyridine: a case for distinct proteolytic mechanisms? Arch Biochem Biophys 294:493-503.
4. Davydov DR (2001) Microsomal monooxygenase in apoptosis: another target for cytochrome c signaling? Trends Biochem Sci 26:155-160.
5. Dong J and Wiley HS (2000) Trafficking and proteolytic release of epidermal growth factor receptor ligands are modulated by their membrane-anchoring domains. J Biol Chem 275:557-564.
6. Eliasson E, Mkrtchian S, Halpert JR, and Ingelman-Sundberg M (1994) Substrate-regulated, cAMP-dependent phosphorylation, denaturation, and degradation of glucocorticoid-inducible rat liver cytochrome P450 3A1. J Biol Chem 269:18378-18383.
7. Gregersen N (2006) Protein misfolding disorders: pathogenesis and intervention. J Inherit Metab Dis 29:456-470.
8. Gu X, Ke S, Liu D, Sheng T, Thomas PE, Rabson AB, Gallo MA, Xie W, and Tian Y (2006) Role of NF-kappaB in regulation of PXR-mediated gene expression: a mechanism for the suppression of cytochrome P-450 3A4 by proinflammatory agents. J Biol Chem 281:17882-17889.
9. Guengerich FP (1995) Human cytochrome P450 enzymes, in Cytochrome P450: Structure, Mechanisms, and Biochemistry (Ortiz de Montellano PR ed) pp 473-535, Plenum Press, New York.
10. Hoffmann A, Natoli G, and Ghosh G (2006) Transcriptional regulation via the NF-kappaB signaling module. Oncogene 25:6706-6716.
11. Jamaluddin M, Wang S, Boldogh I, Tian B, and Brasier AR (2007) TNF-alpha-induced NF-kappaB/RelA Ser(276) phosphorylation and enhanceosome formation is mediated by an ROS-dependent PKAc pathway. Cell Signal 19:1419-1433.
12. Jansson I, Curti M, Epstein PM, Peterson JA, and Schenkman JB (1990) Relationship between phosphorylation and cytochrome P450 destruction. Arch Biochem Biophys 283:285-292.
13. Kaltschmidt B, Ndiaye D, Korte M, Pothion S, Arbibe L, Prullage M, Pfeiffer J, Lindecke A, Staiger V, Israel A, et al. (2006) NF-kappaB regulates spatial memory formation and synaptic plasticity through protein kinase A/CREB signaling. Mol Cell Biol 26:2936-2946.
14. Kimzey AL, Weitz KK, Guengerich FP, and Zangar RC (2003) Hydroperoxy-10,12-octadecadienoic acid stimulates cytochrome P450 3A protein aggregation by a mechanism that is inhibited by substrate. Biochemistry 42:12691-12699.
15. Kliewer SA, Moore JT, Wade L, Staudinger JL, Watson MA, Jones SA, McKee DD, Oliver BB, Willson TM, Zetterstrom RH, et al. (1998) An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 92:73-82.
16. Korsmeyer KK, Davoll S, Figueiredo-Pereira ME, and Correia MA (1999) Proteolytic degradation of heme-modified hepatic cytochromes P450: a role for phosphorylation, ubiquitination, and the 26S proteasome? Arch Biochem Biophys 365:31-44.
17. Krappmann D and Scheidereit C (2005) A pervasive role of ubiquitin conjugation in activation and termination of IkappaB kinase pathways. EMBO Rep 6:321-326.
18. La Ferla K, Reimann C, Jelkmann W, and Hellwig-Burgel T (2002) Inhibition of erythropoietin gene expression signaling involves the transcription factors GATA-2 and NF-kappaB. FASEB J 16:1811-1813.
19. Li N and Karin M (1999) Is NF-kappaB the sensor of oxidative stress? FASEB J 13:1137-1143.
20. Montagut C, Rovira A, and Albanell J (2006) The proteasome: a novel target for anticancer therapy. Clin Transl Oncol 8:313-317.
21. Olivier S, Robe P, and Bours V (2006) Can NF-kappaB be a target for novel and efficient anti-cancer agents? Biochem Pharmacol 72:1054-1068.
22. Pfaffl MW, Horgan GW, and Dempfle L (2002) Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30:e36.
23. Piva R, Belardo G, and Santoro MG (2006) NF-kappaB: a stress-regulated switch for cell survival. Antioxid Redox Signal 8:478-486.
24. Ralstin MC, Gage EA, Yip-Schneider MT, Klein PJ, Wiebke EA, and Schmidt CM (2006) Parthenolide cooperates with NS398 to inhibit growth of human hepatocellular carcinoma cells through effects on apoptosis and G0-G1 cell cycle arrest. Mol Cancer Res 4:387-399.
25. Schmitz A and Herzog V (2004) Endoplasmic reticulum-associated degradation: exceptions to the rule. Eur J Cell Biol 83:501-509.
26. Storz P and Toker A (2003) NF-kappaB signaling-an alternate pathway for oxidative stress responses. Cell Cycle 2:9-10.
27. Szczesna-Skorupa E, Chen CD, Liu H, and Kemper B (2004) Gene expression changes associated with the endoplasmic reticulum stress response induced by microsomal cytochrome P450 overproduction. J Biol Chem 279:13953-13961.
28. Tian Y, Rabson AB, and Gallo MA (2002) Ah receptor and NF-kappaB interactions: mechanisms and physiological implications. Chem Biol Interact 141:97-115.
29. Van Ess PJ, Mattson MP, and Blouin RA (2002) Enhanced induction of cytochrome P450 enzymes and CAR binding in TNF (P55(-/-)/P75(-/-)) double receptor knockout mice following phenobarbital treatment. J Pharmacol Exp Ther 300:824-830.
30. von Bülow V, Dubben S, Engelhardt G, Hebel S, Plumakers B, Heine H, Rink L, and Haase H (2007) Zinc-dependent suppression of TNF-alpha production is mediated by protein kinase A-induced inhibition of Raf-1, IkappaB kinase beta, and NF-kappaB. J Immunol 179:4180-4186.
31. Wang HF, Figueiredo Pereira ME, and Correia MA (1999) Cytochrome P450 3A degradation in isolated rat hepatocytes: 26S proteasome inhibitors as probes. Arch Biochem Biophys 365:45-53.
32. Watkins PB, Bond JS, and Guzelian PS (1987) Degradation of the hepatic cytochromes P-450, in Mammalian Cytochromes P-450 (Guengerich FP ed), vol 2, pp 173-192, CRC Press, Boca Raton, FL.
33. Watkins PB, Wrighton SA, Schuetz EG, Maurel P, and Guzelian PS (1986) Macrolide antibiotics inhibit the degradation of the glucocorticoid-responsive cytochrome P-450p in rat hepatocytes in vivo and in primary monolayer culture. J Biol Chem 261:6264-6271.
34. Zangar RC, Davydov DR, and Verma S (2004) Mechanisms that regulate production of reactive oxygen species by cytochrome P450. Toxicol Appl Pharmacol 199:316-331.
35. Zangar RC, Kocarek TA, Shen S, Bollinger N, Dahn MS, and Lee DW (2003) Suppression of cytochrome P450 3A protein levels by proteasome inhibitors. J Pharmacol Exp Ther 305:872-879.
36. Zhou C, Tabb MM, Nelson EL, Grun F, Verma S, Sadatrafiei A, Lin M, Mallick S, Forman BM, Thummel KE, et al. (2006) Mutual repression between steroid and xenobiotic receptor and NF-kappaB signaling pathways links xenobiotic metabolism and inflammation. J Clin Invest 116:2280-2289.